What is Circle Pharma?
Founded in 2012 and headquartered in San Francisco, Circle Pharma operates at the intersection of computational biology and medicinal chemistry. The company specializes in macro-cyclic peptides, a class of molecules that offer the high specificity of biologics with the cell permeability and oral bioavailability typically associated with small molecules. This unique technological platform allows the firm to tackle challenging protein-protein interactions, effectively expanding the druggable genome. As the company matures, its focus remains on translating these computational insights into a robust pipeline of clinical-stage assets, supported by a sophisticated ecosystem of life science investors and strategic pharmaceutical partners.
How much funding has Circle Pharma raised?
Circle Pharma has raised a total of $297.3M across 4 funding rounds:
Series A
$3.8M
Series B
$45M
Series C
$66M
Series D
$90M
Series A (2016): $3.8M with participation from Mission Bay Capital, ShangPharma Investment Group, Ltd, and Pfizer Inc
Series B (2020): $45M led by The Column Group, Nextech Invest Ltd, ShangPharma Innovation Inc, Lifeforce Capital, and Berkeley Catalyst Fund
Series C (2021): $66M supported by Eli Lilly and Company, Pavillion Capital, Nextech Invest, Pandect Bioventures, Euclidean Capital, Hartford HealthCare Endowment, and The Column Group
Series D (2024): $90M featuring The Column Group, Nextech Invest, and Euclidean Capital
Key Investors in Circle Pharma
The Column Group
A venture ecosystem focused on advancing scientific innovation in the life sciences sector, TCG employs an edge-to-edge investment model that supports companies from inception to exit.
Nextech Invest
A Zurich-based firm dedicated to accelerating advancements in precision medicine by identifying and nurturing transformative cancer medicine companies.
Euclidean Capital
An investment firm focused on strategic capital deployment, currently expanding its service offerings within the broader financial and biotech ecosystem.
What's next for Circle Pharma?
With the successful closure of this latest financing round, Circle Pharma is well-positioned to accelerate its clinical development programs and further refine its discovery platform. The company's strategic trajectory involves scaling its internal research capabilities to advance its lead candidates through human trials while simultaneously exploring new therapeutic indications. Given the firm's history of attracting top-tier venture capital and industry-leading pharmaceutical partners, the current funding context suggests a transition toward late-stage development and potential commercialization milestones. The focus will likely shift toward validating the clinical efficacy of its macro-cyclic peptide candidates, thereby solidifying its competitive advantage in the high-growth biotechnology sector.
See full Circle Pharma company page
